• Ashwini P JSS University
  • Sumana Mn JSS Medical College and Hospital, JSS University, JSS Technical Institution Campus, Manasagangothri, Mysore 570006, Karnataka, India
  • Shilpa U JSS University
  • Mamatha P JSS University
  • Manasa P JSS University
  • Dhananjaya Bl JSS University
  • Farhan Zameer JSS University
  • Nagendra Prasad Mn JSS University


Helicobacter pylori (HP) emergences in gastro intestinal tracts of human beings are one of the major health concerns in recent times. The infection in the later stages can lead to peptic ulcers and gastric cancers. HP is second commonly encountered pathogen in humans next only to Streptococcus. The virulence of the pathogen is further strengthened by its capability in forming biofilms. There are various therapies to treat this infection which are classified as first line, second line and third line, but are not free from the serious antibiotic resistances which normally are encountered in treating bacterial diseases. Vowing to above reason, it is necessary to search for alternative management strategies with lesser side effects and complications like plant based drugs and designer nutraceutical products which includes herbal extracts, probiotics, phytomedicines, antioxidants, essential oils, flavonoids so-on. In the present study, we have reviewed on the thorough understanding on biology, complications and management of H. Pylori and its infections.


Keywords: Peptic ulcers, H. Pylori, Biofilms, Cag A, Vac A, Phytomedicines


Download data is not yet available.


1. George S, David RS. Helicobacter pylori: Eradication or prevention. F1000 Med Reporter 2012;4:7.
2. Oluwasola AO. Genetic determinants and clinico-pathological outcomes of Helicobacter pylori infection. Ann Ibd Pg Med 2014;12(1):22-30.
3. Backert S, Selbach M. Role of type IV secretion in Helicobacter pylori pathogenesis. Cell Microbiol 2008;10:1573-81.
4. Cammarota G, Sanguinetti M, Gallo A, Posteraro B. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Aliment Pharmacol Ther 2012;36:222-30.
5. Steven LP, Louise S. Biofilms and Helicobacter pylori: Dissemination and persistence within the environment and host. World J Gastrointest Pathophysiol 2014;5(3):122-32.
6. Krisztina H, Zsolt T. Helicobacter pylori infection: New pathogenetic and clinical aspects. World J Gastroenterol 2014;20(21):6386-99.
7. Saurabh KP, Chandra BP, Ashok KJ, Anil KG, Gopal N. Diagnosis of Helicobacter pylori: What should be the gold standard? World J Gastroenterol 2014;20(36):12847-59.
8. Amin TBAT. Therapy of Helicobacter pylori: Present Medley and future prospective. Hindawi Publication Corporation; 2014. p. 1-7.
9. Arshad M, Akram M, Shahab-uddin, Afzal A, Khan U, Abdul H, et al. Helicobacter pylori: an introduction 2010;1(3):0976-4550.
10. Jani OR, Gunter B. Morphology and Ultrastructure-Helicobacter pylori-Washington (DC); 2001.
11. Kian M, Frank K. The potential role of N-Acetylcysteine for the treatment of Helicobacter pylori. J Clin Gastroenterol 2011;45(10):841-3.
12. Hideo Y, Takako O, Satoshi K, Minoru F, Hayato K, Kuniyasu O, et al. Outer membrane vesicles of Helicobacter pylori TK1402 are involved in Biofilm Formation. BMC Microbiol 2009;9:197.
13. Aldona B, Monika B, Irena D, Grazyna G. The role of biofilm formation in pathogenesis of Helicobacter pylori infections. Prz Gastroenterol 2013;8(1):27-30.
14. Delia PS, Nina RS. The biology of Helicobacter pylori infection, a major risk factor for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005;14(8):1853-8.
15. Schreiber S, Konradt M, Groll C, Scheid P, Hanauer G, Werling C, et al. The spatial orientation of Helicobacter pylori in the gastric mucus. Proc Natl Acad Scu 2004;101:5024-9.
16. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991;324:1043-8.
17. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997;10:720-41.
18. Markus G, Norbert L, Nina N, Thomas B, Roland R, Wolfgang S, et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. PNAS 1999;96:12778-83.
19. Ludovico B, Eric S, Annemarthe G, Van der Veen, Rino R, Antonello C, et al. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Massachusetts Institute of Technol, Cambridge, PNAS 2011;108(22):9238-43.
20. Daniela B, Carlo-Federico Z, Darren PL, Alessia S, Alberto M, Joanne LR, et al. Clinical Relevance of Helicobacter pylori cagA and vacA Gene Polymorphisms. Gastroenterol 2008;135:91-9.
21. Dacie RB, Scott DM. Polymorphism in the Helicobacter pylori CagA and VacA toxins and disease. Gut Microbes 2013;4(2):101–17.
22. Berg DE, Hoffman PS, Appelmelk BJ, Kusters JG. The Helicobacter pylori genome sequence: genetic factors for long life in the gastric mucosa. Trends Microbiol 1997;5:468-74.
23. Smith MA, Edwards DI. The influence of microaerophilia and anaerobiosis on metronidazole uptake in Helicobacter pylori. J Antimicrob Chemother 1995;36:453-61.
24. Guetarni H, Bensoltane A. Isolation and characterization of Helicobacter pylori strains from gastric biopsies of algerian patients. J Biological Sci 2013;13(2):41-9.
25. Stingl K, Altendorf K, Bakker EP. Acid survival of Helicobacter pylori: how does urease activity trigger cytoplasmic pH homeostasis? Trends Microbiol 2002;10:70-4.
26. Nam-Chul H, Sang-Taek O, Jae YS, Kyeung AC, Mann HL, Byung-Ha O. Supramolecular assembly and acid resistance of Helicobacter pylori urease. Nat Struct Biol 2001;8:505-9.
27. Ana IL, Filipa FV, Monica O. Helicobacter pylori infection-recent developments in diagnosis. World J Gastroenterol 2014;20(28):9299-313.
28. Yagi K, Honda H, Yang JM, Nakagawa S. Magnifying endoscopy in gastritis of the corpus. Endoscopy 2005;37:660-6.
29. Dore MP, Osato MS, Malaty HM, Graham DY. Characterization of a culture method to recover Helicobacter pylori from the feces of infected patients. Helicobacter 2000;5:165-8.
30. Rocha M, Avenaud P, Ménard A, Le Bail B, Balabaud C, Bioulac-Sage P, et al. Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut 2005;54:396-401.
31. Cirak MY, Ozdek A, Yilmaz D, Bayiz U, Samim E, Turet S. Detection of Helicobacter pylori and its CagA gene in tonsil and adenoid tissues by PCR. Arch Otolaryngol Head Neck Surg 2003;129:1225-9.
32. Crabtree J. Immunopathological aspects of Helicobacter pylori associated injury of the gastric mucosa. Mol Med 1994;31:1340–8.
33. Mohammadi M, Nedrud J, Redline R, Lycke N, Czinn SJ. Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load. Gastroenterol 1997;113:1848–57.
34. Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007;56:631-6.
35. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-or, interleukin-1/3 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994;29:4259.
36. Prabhu V, Shivani A. An overview of history, Pathogenesis and treatment of perforated peptic ulcer disease with evaluation of prognostic scoring in adults. Ann Med Health Sci Res 2014;4:22-9.
37. Piazuelo MB, Correa P. Gastric cancer: Overview. Colomb Med 2013;44(3):192-201.
38. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastriccancer. N Engl J Med 2001;345:784-9.
39. Barbara GS, Dun-Fa P, Constanza M, Blanca MP, Liviu AS, Robertino M, et al. Promoter DNA hypermethylation in gastric biopsies from subjects at high and low risk for gastric cancer. Int J Cancer 2010;127(11):2588-97.
40. Huh JH, Park MS, Jeon HH. Early development of reflux esophagitis after successful Helicobacter Pylori eradication in superficial gastritis. J Nepal Med Assoc 2011;51(184):189-91.
41. Vakil N, Van ZSV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20.
42. Anan R, Pali SH, David W, Susan C. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003;326:737.
43. Talley NJ, Hunt RH. What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. Pylori being associated with dyspeptic symptoms. Gastroenterol 1997;113:67-77.
44. Loh KY, Siang TK. Understanding Non Ulcer Dyspepsia. Med J Malaysia 2008;63:174-6.
45. Goh KL. Prevalence of and risk factors for Helicobacter pylori infection in a multi-racial dyspeptic Malaysian population undergoing endoscopy. J Gastroenterol Hepatol 1997;12(6):29-35.
46. Alberto P, Marilisa F. Helicobacter pylori infection in older. World J Gastroenterol 2014;20(21):6364-73.
47. Pelayo C, Blanca P. The gastric precancerous cascade. J Dig Dis 2012;13(1):2-9.
48. Chey WD, Wong BC. American college of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
49. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States. Dig Dis Sci 2000;45:265–71.
50. Saad RJ, Chey WD. Treatment of Helicobacter pylori infection in 2006. Gastroenterol Hepatol Annu Rev 2006;1:30-5.
51. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010:59(8):1143-53.
52. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011;17(35):3971-5.
53. Gisbert JP. Rescue regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008;21:1-14.
54. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690–700.
55. Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008;14:7361-70.
56. Gisbert JP, Perez-Aisa A, Castro-Fernandez M, Barrio J, Rodrigo L, Cosme A, et al. Helicobacter pylori first-line treatment and rescue option containinglevofloxacin in patients allergic to penicillin. Dig Liver Dis 2010;42(4):287-90.
57. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006;11(5):441-5.
58. Manfredi M, Bizzarri B, Manzali E, Fugazza A, Gismondi P, Luigi GA. Which Treatment in Helicobacter pylori Infection? Clin Exp Pharmacol 2013;3:139.
59. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, et al. Rifabutin-and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first-and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005;2:91-6.
60. Cammarota G, Martino A, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, et al. High efficacy of 1-week doxycycline-and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacterpylori infection. Aliment Pharmacol Ther 2004;19(7):789-95.
61. Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, et al. The effects of probiotics on PPItriple therapy for Helicobacter pylori eradication. Helicobacter 2008;13:261-8.
62. Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, Novisci D, et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterol 2008;135:787-95.
63. Anna B, Vizma N, Dmitry B. Anti-Helicobacter activity of certain food plant extracts and juices and their composition in vitro. Food Nutr Sci 2011;2:868-77.
64. Yuan-Chuen Wang. Medicinal plant activity on Helicobacter pylori related diseases. World J Gastroenterol 2014;20(30):10368-82.
65. Ananya C, Sandip KB. Herbal remedy: An alternate therapy of nonsteroidal anti-inflammatory drug induced gastric ulcer healing. Hindawi Publishing Corporation Ulcers; 2014. p. 1-13.
66. Pastene E, Speisky H, Garc´ıa A, Moreno J, Troncoso M, Figueroa G. In vitro and in vivo effects of apple peel polyphenols against Helicobacter pylori. J Agric Food Chem 2010;58(12):7172–9.
67. Mohammad HF, Mohammad RS, Zahra A, Roja R. Scientific evaluation of edible fruits and spices used for the treatment of peptic ulcer in traditional iranian medicine. Hindawi Publishing Corporation ISRN Gastroenterology; 2013. p. 1-12.
68. Jae MK, Hong MZ, Lee BY, Lee WK, Lee DH. Anti-Helicobacter pylori Properties of GutGard. Prev Nutr Food Sci 2013;18(2):104-10.
69. Rachel OM, Huda AK, Deepaka W, Neluka F, Dino V, John H, et al. Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World J Gastroenterol 2005;11(47):7499-507.
70. Ronita D, Parag K, Snehasikta S, Ramamurthy T, Abhijit C, Balakrish GN, et al. Antimicrobial activity of curcumin against Helicobacter pylori Isolates from India and during Infections in Mice. Antimicrob Agents Chemother 2009;3:1592–7.
71. Kiranmai M, Syed AB, Mahendra KCB, Mohammed I. Exploring medicinal plants for Anti-Helicobacter Pylori activity. Global J Med Res 2012;12(4):33-8.
72. Calin S, Reza S, Jean MH. Green tea inhibits Helicobacter growth in vivo and in vitro. Int J Antimicrob Agents 2009;33(5):473-8.
73. Gail BM, Susan LP, Gina S Yun, Zhi-Zhen Lu, Adina Stoia. Ginger (Zingiber officinale Roscoe) and the Gingerols Inhibit the Growth of Cag A+Strains of Helicobacter pylori. NIH Public Access Author Manuscript. Anticancer Res. 2003;23:3699-702.
74. Bhamarapravati S, Juthapruth S, Mahachai W, Mahady G. Antibacterial activity of Boesenbergia rotunda (L.) mansf. And Myristica fragrans houtt. against Helicobacter pylori. Songklanakarin. J Sci Technol 2006;28(1):157-63.
75. Guadalupe A, Wendy IEH, Carlos FCH, Irma R. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014;20(6):1450-69.
76. Esmaeili D, Mohabati MA, Tohidpour A. Anti-Helicobacter Pylori activities of shoya powder and essential oils of Thymus Vulgaris and eucalyptus globulus. Open Microbiol J 2012;6:65-9.
77. Ansari N, Siddiquian. A review on phytochemistry and pharmacological Pistacia lentiscus. Int J Pharm Pharm Sci 2012;4:16-20.
78. Miyamoto T, Okimoto T, Kuwano M. Chemical Composition of the essential oil of mastic gum and their antibacterial activity against drug-resistant Helicobacter pylori. Nat Prod Bioprospect 2014;4:227-31.
79. Bergonzelli GE, Donnicola D, Porta N, Corthesy I. Essential oils as components of a diet-based approach to management of Helicobacter Infection. Antimicrob Agents Chemother 2003;47:3240-6.
80. Farhan Zameer, Shubha Gopal, Georg Krohne, Juergen Kreft. Development of a biofilm model for Listeria monocytogenes. World J Microbiol Biotechnol 2009;26(6):1143-7.
81. Farhan Zameer, Juergen Kreft, Shubha Gopal. Interaction of the dual species biofilms of Listeria monocytogenes and Staphylococcus epidermidis. J Food Saf 2010;30(4):954-68.
520 Views | 4175 Downloads
How to Cite
P, A., S. Mn, S. U, M. P, M. P, D. Bl, F. Zameer, and N. P. Mn. “A REVIEW ON HELICOBACTER PYLORI: ITS BIOLOGY, COMPLICATIONS AND MANAGEMENT”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 13, May 2015, pp. 14-20, https://innovareacademics.in/journals/index.php/ijpps/article/view/4169.